MannKind today announced six-month results from its Phase 3 INHALE-1 study of Afrezza insulin inhalation powder in children.

(RTTNews) - MannKind Corporation (MNKD) Monday reported positive six-month results from its Phase 3 INHALE-1 study of Afrezza Inhalation Powder, a rapid-acting inhaled human insulin, in individuals ...

Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression The INHALE-1 study is a 26-week, ...

Cipla secures CDSCO approval for Afrezza, its inhaled insulin, marking a breakthrough in diabetes management with innovative ...

Objective, but not subjective, EDS was associated with insulin resistance and disordered glucose metabolism among patients with OSA.

Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.

MannKind and Cipla announce CDSCO approves Afrezza inhalation powder in India: Our Bureau, Mumbai Thursday, December 12, 2024, 17:30 Hrs [IST] MannKind Corporation, a company focu ...

Mumbai: Cipla Limited has announced that it has obtained regulatory approval from Central Drugs Standard Control Organisation ...

Shares of firms like Jubilant FoodWorks, Maruti Suzuki, Swiggy, SBI, Vedanta, and others will be in focus on Thursday's trade ...

Greaves Cotton board approved OFS of certain shares of arm Greaves Electric held by the company in the proposed IPO.

Indian regulator Central Drugs Standard Control Organisation (CDSCO) has approved Cipla to exclusively distribute and market ...